The G0/G1 Switch Gene 2 Is an Important Regulator of Hepatic Triglyceride Metabolism

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wang, Yinfang ^a   Zhang, Yahui ^a   Qian, Hang ^a   Lu, Juan ^a   Zhang, Zhifeng ^a   Min, Xinwen ^a   Lang, Mingjian ^a   Yang, Handong ^a   Wang, Nanping ^b   Zhang, Peng ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 [N (7 NITROBENZ 2 OXA 1 3 DIAZOL 4 YL)AMINO] 6 DEOXYGLUCOSE; ADENOVIRUS VECTOR; CARBOHYDRATE DERIVATIVE; CHOLESTEROL; FAT DROPLET; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETONE BODY; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG TARGETING; FATTY LIVER; G0 G1 SWITCH GENE 2; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC REGULATION; GENETIC TRANSFECTION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; LIVER METABOLISM; LIVER WEIGHT; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FATTY LIVER; GENE EXPRESSION; GLUCOSE; HEPATOCYTES; HUMANS; KETONE BODIES; LIPID METABOLISM; LIVER; MALE; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84881484385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072315     Document Type: Article

References (38)

1. Leavens KF, Birnbaum MJ, (2011) Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 46: 200-215. doi:10.3109/10409238.2011.562481. PubMed: 21599535.
2. Richard J, Lingvay I, (2011) Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 9: 321-328. doi:10.1586/erc.11.15. PubMed: 21438811.
3. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353. doi:10.1074/jbc.M313478200. PubMed: 15166226.
4. Santos RD, Nasir K, Conceição RD, Sarwar A, Carvalho JA, et al. (2007) Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. Atherosclerosis 194: 517-519. doi:10.1016/j.atherosclerosis.2007.01.026. PubMed: 17335826.
5. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-388. doi:10.1016/j.cmet.2011.03.009. PubMed: 21459323.
6. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, et al. (2004) Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27: 2498-2500. doi:10.2337/diacare.27.10.2498. PubMed: 15451925.
7. Marmugi A, Ducheix S, Lasserre F, Polizzi A, Paris A, et al. (2012) Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. Hepatology 55: 395-407. doi:10.1002/hep.24685. PubMed: 21932408.
8. Ong KT, Mashek MT, Bu SY, Greenberg AS, Mashek DG, (2011) Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 53: 116-126. doi:10.1002/hep.24006. PubMed: 20967758.
9. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, et al. (2006) Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55: 2042-2050. doi:10.2337/db05-0705. PubMed: 16804074.
10. Nakamura N, Shimaoka Y, Tougan T, Onda H, Okuzaki D, et al. (2006) Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res 13: 169-183. doi:10.1093/dnares/dsl006. PubMed: 17082220.
11. Russell L, Forsdyke DR, (1991) A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol 10: 581-591. doi:10.1089/dna.1991.10.581. PubMed: 1930693.
12. Zandbergen F, Mandard S, Escher P, Tan NS, Patsouris D, et al. (2005) The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 392: 313-324. doi:10.1042/BJ20050636. PubMed: 16086669.
13. Teunissen BE, Smeets PJ, Willemsen PH, De Windt LJ, Van der Vusse GJ, et al. (2007) Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 75: 519-529. doi:10.1016/j.cardiores.2007.04.026. PubMed: 17543901.
14. Cheng YH, Utsunomiya H, Pavone ME, Yin P, Bulun SE, (2011) Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. J Mol Endocrinol 46: 139-153. doi:10.1530/JME-10-0064. PubMed: 21310893.
15. Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, et al. (2008) G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 33: 397-404. PubMed: 18636162.
16. Yang X, Lu X, Lombès M, Rha GB, Chi YI, et al. (2010) The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab 11: 194-205. doi:10.1016/j.cmet.2010.02.003. PubMed: 20197052.
17. Bächner D, Ahrens M, Schröder D, Hoffmann A, Lauber J, et al. (1998) Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev Dyn 213: 398-411. doi:10.1002/(SICI)1097-0177(199812)213:4. PubMed: 9853961.
18. Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, et al. (2003) CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 426: 190-193. doi:10.1038/nature02110. PubMed: 14614508.
19. Latruffe N, Passilly P, Jannin B, Motojima K, Cherkaoui Malki M, et al. (2000) Relationship between signal transduction and PPAR alpha-regulated genes of lipid metabolism in rat hepatic-derived Fao cells. Cell Biochem Biophys 32: 213-220. doi:10.1385/CBB:32:1-3:213. PubMed: 11330049.
20. Edvardsson U, Ljungberg A, Lindén D, William-Olsson L, Peilot-Sjögren H, et al. (2006) PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 47: 329-340. PubMed: 16282640.
21. Waterman IJ, Zammit VA, (2002) Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51: 1708-1713. doi:10.2337/diabetes.51.6.1708. PubMed: 12031956.
22. Ljung B, Bamberg K, Dahllöf B, Kjellstedt A, Oakes ND, et al. (2002) AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43: 1855-1863. doi:10.1194/jlr.M200127-JLR200. PubMed: 12401884.
23. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, et al. (2002) WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277: 24484-24489. doi:10.1074/jbc.M202449200. PubMed: 11994294.
24. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, et al. (2009) Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 158: 706-712. doi:10.1111/j.1476-5381.2009.00350.x. PubMed: 19694729.
25. Pan SY, Yang R, Dong H, Yu ZL, Ko KM, (2006) Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol 552: 170-175. doi:10.1016/j.ejphar.2006.09.011. PubMed: 17046746.
26. Srivastava RA, (2009) Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists. Eur J Pharmacol 607: 258-263. doi:10.1016/j.ejphar.2009.02.024. PubMed: 19245804.
27. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, et al. (2011) ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 17: 1076-1085. doi:10.1038/nm.2439. PubMed: 21857651.
28. Ong KT, Mashek MT, Bu SY, Mashek DG, (2012) Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation. FASEB J 27: 313-321. PubMed: 22993196.
29. Lu X, Yang X, Liu J, (2010) Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2. Cell Cycle 9: 2719-2725. doi:10.4161/cc.9.14.12181. PubMed: 20676045.
30. Cohen JC, Horton JD, Hobbs HH, (2011) Human fatty liver disease: old questions and new insights. Science 332: 1519-1523. doi:10.1126/science.1204265. PubMed: 21700865.
31. Ma L, Robinson LN, Towle HC, (2006) ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 281: 28721-28730. doi:10.1074/jbc.M601576200. PubMed: 16885160.
32. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, et al. (2003) Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52: 2905-2913. doi:10.2337/diabetes.52.12.2905. PubMed: 14633850.
33. Xu A, Lam MC, Chan KW, Wang Y, Zhang J, et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 102: 6086-6091. doi:10.1073/pnas.0408452102. PubMed: 15837923.
34. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, et al. (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc Natl Acad Sci U S A 101: 2082-2087. doi:10.1073/pnas.0308617100. PubMed: 14769918.
35. Hoy AJ, Bruce CR, Turpin SM, Morris AJ, Febbraio MA, et al. (2011) Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation. Endocrinology 152: 48-58. doi:10.1210/en.2010-0661. PubMed: 21106876.
36. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, et al. (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312: 734-737. doi:10.1126/science.1123965. PubMed: 16675698.
37. Badin PM, Louche K, Mairal A, Liebisch G, Schmitz G, et al. (2011) Altered skeletal muscle lipase expression and activity contribute to insulin resistance in humans. Diabetes 60: 1734-1742. doi:10.2337/db10-1364. PubMed: 21498783.
38. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 108: 16381-16385. doi:10.1073/pnas.1113359108. PubMed: 21930939.